Stock Chart

AKBA

$1.38 -2.13%
Score: 52.6 HOLD
1Y Target $1.35 -2.2%
i
1Y Price Target

This target is derived from long-term trendline analysis and projected growth.

Note: Targets are based on the assumption that the current primary trend continues. They should be used as reference points, not guarantees.

Target may adjust dynamically as the stock trend reverses or accelerates.
LEAPs: SELL $2
i
LEAPs Option Signal

Type: SELL growth_1yr
Strike: $2
Premium: $0.55
Expiry: Jan 15, 2027
Target: $1
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $1.23 - $1.5 STRONG_DOWNTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.79
Vol: 1.28x (vs SPY: 1.3x | vs QQQ: 1.4x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About AKBA - Akebia Therapeutics, Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral …

Key Statistics

Market Cap $374M

This AKBA stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track AKBA's price movements with trendlines, gamma walls, and key support/resistance levels.